New developments in psychopharmacology of attention deficit hyperactivity disorder

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Stimulants have been the mainstay of the psychopharmacological treatment of attention deficit hyperactivity disorder (ADHD) for over 60 years. In the last 5 years, there have been a number of important developments in terms of potential new treatments for ADHD. Since stimulants have such a short half-life, considerable research has focused on the development of new delivery systems that will allow once-a-day dosing. New formulations of both amphetamine (AMP) and methylphenidate (MPH) have appeared which differ in terms of their optical isomers from the commonly used compounds. A wide variety of compounds are currently in development as therapeutic agents for ADHD. Some, like the stimulants, primarily impact the noradrenergic and dopaminergic neurotransmitter systems, while others have novel effects on the cholinergic, histaminergic and peptidergic systems. Advances in the pharmacogenetics of ADHD may lead to the development of yet more compounds in the near future.

Original languageEnglish (US)
Pages (from-to)1797-1807
Number of pages11
JournalExpert Opinion on Investigational Drugs
Issue number10
StatePublished - 2001


  • ADHD
  • Dopamine
  • Norepinephrine
  • Psychopharmacology
  • Stimulants

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'New developments in psychopharmacology of attention deficit hyperactivity disorder'. Together they form a unique fingerprint.

Cite this